Hangzhou Zhongmei Huadong Pharmaceutical Co. Ltd. has divulged antibody-drug conjugates (ADCs) comprising antibodies targeting human mucin-17 (MUC17) covalently linked to a cytotoxic drug through a linker reported to be useful for the treatment of cancer.

Bionova Pharmaceuticals Ltd. has identified methylthioadenosine (MTA) synergistic protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer.

Shanghai Huilun Pharmaceutical Co. Ltd. has synthesized type 2 angiotensin II receptor (AGTR2; AT2) antagonists reported to be useful for the treatment of pain, particularly neuropathic pain.

Bugworks Research India Pvt Ltd. has disclosed cyclin-dependent kinase 7 (CDK7) inhibitors reported to be useful for the treatment of cancer.

Shanghai Institute of Materia Medica of the Chinese Academy of Sciences has described isocitrate dehydrogenase (NADP) cytoplasmic (IDH1; PICD; IDP) (mutant) inhibitors reported to be useful for the treatment of glioma.

Chengdu Kanghong Pharmaceutical Co. Ltd. has identified DNA polymerase θ (POLθ) inhibitors reported to be useful for the treatment of cancer.

Shanghai Yingli Pharmaceutical Co. Ltd. has divulged phosphatidylinositol 3-kinase α (PI3Kα) (H1047R mutant) inhibitors reported to be useful for the treatment of cancer.

Nanjing Zaiming Pharmaceutical Co. Ltd. has synthesized Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors reported to be useful for the treatment of cancer.

Almirall SA has disclosed tyrosine-protein kinase ITK/TSK (EMT) inhibitors reported to be useful for the treatment of atopic dermatitis, psoriasis, alopecia areata, vitiligo, T-cell lymphoma, asthma, inflammatory bowel disease and multiple sclerosis, among others.

Merck Sharp & Dohme LLC and Peloton Therapeutics Inc. have described transcriptional coactivator YAP1/transcriptional enhancer factor (TEAD) interaction inhibitors reported to be useful for the treatment of cancer.